中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2015, Vol. 10 ›› Issue (5): 832-840.doi: 10.4103/1673-5374.156991

• 综述:脑损伤修复保护与再生 • 上一篇    

能更好发挥保护脑缺血再灌注损伤的川芎嗪单体

  

  • 收稿日期:2015-04-20 出版日期:2015-05-15 发布日期:2015-05-15
  • 基金资助:

    黑龙江省卫计委项目(2014-195)，黑龙江省教育厅项目(12531741)

Ligustrazine monomer against cerebral ischemia/reperfusion injury

Hai-jun Gao 1, 2, Peng-fei Liu 1, Pei-wen Li 1, Zhuo-yan Huang 3, Feng-bo Yu 4, Ting Lei 1, Yong Chen 1, Ye Cheng 1, Qing-chun Mu 2, Hai-yan Huang 1   

  1. 1 Department of Neurosurgery, First Bethune Hospital of Jilin University, Changchun, Jilin Province, China
    2 Department of Neurosurgery, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang Province, China
    3 Clinical Medical College of Beihua University, Jilin, Jilin Province, China
    4 School of Pharmacy, Mudanjiang Medical University, Mudanjiang, Heilongjiang Province, China
  • Received:2015-04-20 Online:2015-05-15 Published:2015-05-15
  • Contact: Qing-chun Mu, M.D., Ph.D. or Hai-yan Huang, M.D., Ph.D.,muqcns@gmaill.com or huanghy@jlu.edu.cn.
  • Supported by:

    This work was supported by a grant from the Health and Family Planning Commission of Heilongjiang Province Research Project in China, No. 2014-195; the Education Department Science and Technology Foundation of Heilongjiang Province in China, No. 12531741; the Natural Science Foundation of Heilongjiang Province of China, No. H2015083.

PDF

1060

摘要：

川芎嗪全名天然四甲基吡嗪，是中药川芎的主要有效成分，在临床上被广泛用于缺血性脑血管疾病的治疗，其药物作用机制目前尚不明确。文章就川芎嗪在抑制兴奋性氨基酸释放；促进内源性神经干细胞的迁移、分化、增殖；促进脑缺血后血管再生；抑制血栓形成；抑制炎症反应；抑制细胞凋亡等方面对脑缺血再灌注损伤的保护性作用、给药时间窗、给药方式选择及临床应用等多个方面进行文献综述。认为川芎嗪对脑缺血再灌注损伤具有较为显著的保护性作用，鉴于其作用时间窗的局限性，川芎嗪的一系列衍生物单体如TBN、CXC137、CXC195等，在保留川芎嗪药理学特性(吡嗪环)的基础上，对缺血后脑组织的保护性作用、给药时间窗方面优于川芎嗪。

关键词: 神经再生, 中医药, 川芎嗪, 单体, 缺血, 疾病, 脑缺血再灌注损伤, 给药时间窗, 给药方式, 作用机制, 临床应用, 实验研究进展

Abstract:

Ligustrazine (2,3,5,6-tetramethylpyrazine) is a major active ingredient of the Szechwan lovage rhizome and is extensively used in treatment of ischemic cerebrovascular disease. The mechanism of action of ligustrazine use against ischemic cerebrovascular diseases remains unclear at present. This study summarizes its protective effect, the optimum time window of administration, and the most effective mode of administration for clinical treatment of cerebral ischemia/reperfusion injury. We examine the effects of ligustrazine on suppressing excitatory amino acid release, promoting migration, differentiation and proliferation of endogenous neural stem cells. We also looked at its effects on angiogenesis and how it inhibits thrombosis, the inflammatory response, and apoptosis after cerebral ischemia. We consider that ligustrazine gives noticeable protection from cerebral ischemia/reperfusion injury. The time window of ligustrazine administration is limited. The protective effect and time window of a series of derivative monomers of ligustrazine such as 2-[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, CXC137 and CXC195 after cerebral ischemia were better than ligustrazine.

Key words: nerve regeneration, ligustrazine, ischemia, cerebral ischemia/reperfusion injury, neural regeneration